{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:18:25Z","timestamp":1784053105135,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ajoc.2024.102074","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T06:48:08Z","timestamp":1716533288000},"page":"102074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Durvalumab-associated limbal stem cell deficiency and secondary corneal perforation"],"prefix":"10.1016","volume":"35","author":[{"given":"Nahrain Putris","family":"Schumaier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Heidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajoc.2024.102074_bib1","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"AUG","key":"10.1016\/j.ajoc.2024.102074_bib2","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajoc.2024.102074_bib3","series-title":"Imfinzi (Durvalumab) Injection, for Intravenous Use [Prescribing Information]","author":"AstraZeneca Pharmaceuticals","year":"2017"},{"issue":"3","key":"10.1016\/j.ajoc.2024.102074_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","article-title":"Ocular adverse events with immune checkpoint inhibitors","volume":"31","author":"Fang","year":"2019","journal-title":"J Curr Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajoc.2024.102074_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002119","article-title":"Ocular adverse events in PD-1 and PD-L1 inhibitors","volume":"9","author":"Young","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ajoc.2024.102074_bib6","volume":"vol. 38","author":"Dalvin","year":"2018"},{"issue":"12","key":"10.1016\/j.ajoc.2024.102074_bib7","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s00262-020-02635-3","article-title":"Factors associated with ocular adverse event after immune checkpoint inhibitor treatment","volume":"69","author":"Kim","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"10.1016\/j.ajoc.2024.102074_bib8","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.3390\/jcm11195647","article-title":"Corneal transplant rejections in patients receiving immune checkpoint inhibitors","volume":"11","author":"Moshirfar","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.ajoc.2024.102074_bib9","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.4049\/jimmunol.179.6.3672","article-title":"The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival","volume":"179","author":"Shen","year":"2007","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ajoc.2024.102074_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1167\/iovs.08-2397","article-title":"PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation","volume":"50","author":"Yang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ajoc.2024.102074_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-023-00460-1","article-title":"Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy","volume":"11","author":"Zhang","year":"2023","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.ajoc.2024.102074_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/ICO.0000000000002490","article-title":"Bilateral corneal perforation in a patient under anti-PD1 therapy","volume":"40","author":"Ramaekers","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.ajoc.2024.102074_bib13","article-title":"Bilateral corneal perforation in Ipilimumab\/Nivolumab - associated peripheral ulcerative keratitis","volume":"28","author":"Aschauer","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"10.1016\/j.ajoc.2024.102074_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ICO.0000000000000724","article-title":"Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation","volume":"35","author":"Nguyen","year":"2016","journal-title":"Cornea"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993624000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993624000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T03:10:26Z","timestamp":1718939426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993624000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":14,"alternative-id":["S2451993624000847"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2024.102074","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab-associated limbal stem cell deficiency and secondary corneal perforation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2024.102074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102074"}}